WHITEHAWK THERAPEUTICS, INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
WHITEHAWK THERAPEUTICS, INC. (WHWK) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-13.
Discontinued › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2024-03-13
- WHITEHAWK THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- WHITEHAWK THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-09-30 was $0.00.
- WHITEHAWK THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-12-31 was $31.00K.
- WHITEHAWK THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-09-30 was $0.00, a 100.00% decline year-over-year.
- WHITEHAWK THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- WHITEHAWK THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $1.24M, a 103.44% increase from fiscal 2021.
- WHITEHAWK THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2021 was $610.00K.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $0.00 derived: sum of 2 quarters · filed 2024-03-13 | $0.00 10-K · filed 2024-03-13 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $0.00 10-Q · filed 2023-11-08 | ||
| 2023-06-30 | $0.00 10-Q · filed 2023-08-09 | |||
| 2022-12-31 | $31.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $31.00K derived: sum of 2 quarters · filed 2024-03-13 | $1.24M 10-K · filed 2024-03-13 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $1.21M 10-Q · filed 2023-11-08 | ||
| 2022-06-30 | $1.21M 10-Q · filed 2023-08-09 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $610.00K derived: sum of 2 quarters · filed 2023-03-29 | $610.00K 10-K · filed 2023-03-29 | |
| 2021-09-30 | $610.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $610.00K 10-Q · filed 2022-11-09 | ||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |